We performed an open-label, observational study using historical baseline data and a prospective treatment phase in order to assess patient treatment satisfaction pre- and post- triptan treatment with 50mg Sumatriptan tablets and preference for Sumatriptan compared to previous non-triptan therapy for migraine headache over a three month period. Patients were recruited from an internal medicine subspecialty clinic either by recommendation of their physician or by responding to flyers offering the study in physician and laboratory waiting areas and a monthly bill insert. We included patients older than 18 years but not more than 65 years of age with at least a 1-year history of disabling headaches meeting the I.H.S. criteria for migraine with/without aura (I.H.S. 1.1, 1.2) and with a frequency of 2-8 migraines per month. Patients were free from active cardiovascular disease and were previously using non-triptans for first-line migraine treatment. Patients were asked to complete a questionnaire detailing their level of satisfaction regarding varying aspects of their prior migraine care as well as medical resource utilization and missed employment. Patients were asked what therapy they were using for migraine and why they were not using triptan therapy. Patients were then given Sumatriptan 50 mg capsules. They returned for an interim visit at one-month and then a final visit at 3 months. They then completed a questionnaire detailing their level of satisfaction regarding varying aspects of their prior migraine care as well as medical resource utilization and missed employment. They were then asked their preference between Sumatriptan and their prior therapy.